A Failed Phase 3 Drug Shows Signs of Life in Follow-On Data
Fasedienol missed its Phase 3 goal in June. The open-label follow-on data looks more encouraging — but there was no placebo group to compare against.
Venue
nasdaq
Exchange-listed, but small. These companies file with the SEC — and have to hold on to their listing.
Stories
151
Updated
24 Sep
More on Nasdaq
A Tiny Energy-Storage Stock Is Shrinking Its Share Count to Stay Listed
This Coffee Chain Has Until November to Convince Nasdaq It Can Stay Listed
A Convicted Founder's Claims Could Vanish Into Thin Air
A Tiny Biotech Says Its Ebola Drug Beat Remdesivir in the Lab
A Freight Broker Is Spending Tens of Millions on GPU Servers
The FDA Unblocked This Drug Trial. Nasdaq May Delist the Company Anyway.
Innventure Halves Its Own Costs and Bets Everything on One Subsidiary
A Tiny Optics Maker Just Landed Its Biggest Defense Order Ever
New Era Signed a Power Deal with Vistra. The Bill Arrives First.
Priority's CEO Already Runs the Company. Now He's Buying It.
NuRAN Wireless Opens a Share Tap to Fund Its African Build
A 3D Perception Company Is Building a Full Autonomous Stack for Drones and Ground Robots
Canaan Cashed Out Its Crypto Treasury to Buy Back Its Own Shares
$6 Million in Revenue. A $200 Million Mandate.
A Solana Treasury Company Just Opened a New Preferred Stock Funding Engine